唑来膦酸联合来曲唑治疗对绝经期乳腺癌术后生命质量的改善

探讨唑来膦酸联合来曲唑改善绝经期乳腺癌术后生命质量的治疗效果。方法：49例绝经期乳腺癌术后患者随机分为2组，观察组23例联合应用唑来膦酸和来曲唑，对照组26例单纯口服来曲唑。于术后6，12个月检测两组患者的骨密度（BMD）和血清骨特异性碱性磷酸酶（BALP）、I型胶原c端肽（CTX），VAS评分镇痛效果，乳腺癌治疗功能评价系统（FACT-B）生命质量评分等指标并作比较。结果：观察组骨密度和FACT—B生命质量评分较对照组改善明显（P〈0．05或0．01），观察组6，12个月时VAS评分、血清BALP水平、CTX含量等指标均较对照组明显减低（P〈0．05）。病变远处转移发生率两组差异无统计学意义（P〉0．05）。结论：唑来膦酸能有效改善来曲唑引起骨量丢失等不良反应，调高镇痛效果减低骨折风险发生提高患者生命质量。．

Improvement in Life Quality of Postmenopausal Women with Breast Cancer Operation by Zoledronic Acid and Letrozole

To study the treatment effect of zoledronic acid and letrozole on life quality of postmenopausal women with breast cancer operation. Methods： Totally 26 patients were in the control group, and given letrozole, and 23 patients were in the treat- ment group with zoledronic and letrozole. The patients in the two groups were assessed bone mineral density （BMD） of hip and lumbar vertebrate before the treatment and the 6th and 12th month after the treatment. BALP, CTX, VAS, FACT-B and adverse reactions were also assessed at the 6th and 12th month after the treatment. Results： Improvement of BMD and FACT-B in the treatment group was sig- nificantly better than that in the control group. BALP, CTX and VAS in the treatment group were all decreased more significantly than those in the control group （P 〈0.05 or P 〈0.01 ）. Thei＇e was no significant difference in the metastasis between the two groups （P 〉 0.05）. Conclusion： By preventing bone loss and increasing BMD, the combination of zoledronic acid and letrozole can effectively im- prove the life quality of postmenopansal women with breast cancer operation.